Organigram Story

<div class='circular--portrait' style='background:#800000;color: #F8F8FF;font-size:4em;'>OH</div>
OGI -- USA Stock  

USD 1.72  0.02  1.15%

As many of us are excited about healthcare space, it is fair to concentrate on Organigram Hlds. We will evaluate why we are still confident in anticipation of a recovery. Is the firm current valuation justified? We will cover Organigram Hlds valuation to give you a better outlook on taking a position in the stock.
Published over a week ago
View all stories for Organigram Hlds | View All Stories
Is Organigram Hlds outlook positive for February 2021?
Organigram Hlds has 59.39 M in debt with debt to equity (D/E) ratio of 0.4, which is OK given its current industry classification. Organigram Hlds holds a performance score of 27 on a scale of zero to a hundred. The company holds a Beta of -0.3405, which implies possible diversification benefits within a given portfolio. Let's try to break down what Organigram's beta means in this case. As returns on the market increase, returns on owning Organigram Hlds are expected to decrease at a much lower rate. During the bear market, Organigram Hlds is likely to outperform the market. Although it is essential to pay attention to Organigram Hlds current trending patterns, it is also good to be reasonable about what you can do with equity existing price patterns. Our philosophy towards forecasting future performance of any stock is to look not only at its past charts but also at the business as a whole, including all fundamental and technical indicators. To evaluate if Organigram Hlds expected return of 1.74 will be sustainable into the future, we have found twenty-seven different technical indicators, which can help you to check if the expected returns are sustainable. Use Organigram Hlds total risk alpha, expected short fall, price action indicator, as well as the relationship between the value at risk and daily balance of power to analyze future returns on Organigram Hlds.
We determine the current worth of Organigram Hlds using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Organigram Hlds based exclusively on its fundamental and basic technical indicators. By analyzing Organigram Hlds's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Organigram Hlds's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Organigram Hlds. We calculate exposure to Organigram Hlds's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Organigram Hlds's related companies.

Organigram Hlds Investment Alerts

Organigram investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Organigram Hlds performance across your portfolios.Please check all investment alerts for Organigram

Organigram Hlds Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Organigram value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Organigram Hlds competition to find correlations between indicators driving the intrinsic value of Organigram.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions. It is good to see analyst projects for Organigram Hlds, but it might be worth checking our own buy vs. sell analysis

Breaking it down a bit more

The entity reported the last year's revenue of 99.78 M. Reported Net Loss for the year was (11.26 M) with loss before taxes, overhead, and interest of (50.4 M).

Margins Breakdown

Organigram profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Organigram Hlds itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Organigram Hlds profit margins.
EBITDA Margin(1.37)
Gross Margin(0.61)
Profit Margin(1.45)


Organigram Hlds Earnings before Tax is nearly stable at the moment. Further, Organigram Hlds Average Equity is nearly stable at the moment.

Will Organigram Hlds current rise continue?

The market risk adjusted performance is down to -2.31 as of today. Organigram Hlds shows above-average downside volatility for the selected time horizon. We advise investors to inspect Organigram Hlds further and ensure that all market timing and asset allocation strategies are consistent with the estimation of Organigram Hlds future alpha.

Our Final Take On Organigram Hlds

While some other firms within the drug manufacturers?specialty & generic industry are still a little expensive, even after the recent corrections, Organigram Hlds may offer a potential longer-term growth to stockholders. All things considered, as of the 11th of January 2021, our final 30 days recommendation on the company is Strong Sell. However, we believe Organigram Hlds is undervalued with low chance of distress for the next two years.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Organigram Hlds. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com